In ER+ SELENBP1 high expressing breast cancer cells, addition of exogenous estrogen downregulated SELENBP1 expression, and knocking down SELENBP1 confers the cell resistance to selenium treated cell proliferation inhibition. Here, ESR1 is linked to breast carcinoma.